Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Esperion Therapeutics (ESPR) – Form 4 insider filing: Chief Financial Officer Benjamin Halladay reported the sale of 7,229 common shares on 06/17/2025 at $1.152 per share, generating roughly $8,300 in proceeds. The company states the disposition was made solely to cover withholding taxes on recently-vested RSUs. Following the transaction, Halladay still directly holds 474,473 ESPR shares. No derivative transactions or additional dispositions were disclosed, and the filing indicates the sale was effected under a routine tax-settlement, not a 10b5-1 trading plan.